Literature DB >> 1730276

Incidence of polycythemia vera in a defined population.

S Berglund1, O Zettervall.   

Abstract

In this retrospective investigation from Malmö, a city well-suited for epidemiologic studies, 177 patients (88 males and 89 females) with polycythemia vera (PV) were identified between 1950 and 1984. The incidence rate (number of cases/100,000/yr) in both sexes increased significantly, being 1.0 in 1950-1959 and 2.6 in 1980-1984 (adjusted to the European age-standardized population). This is the highest rate reported to date. In 1970-1984 the highest age-specific incidence rates (number of cases/100,000/yr) were found in males greater than or equal to 80 yr and females 70-79 yr of age, being 18.3 and 14.6, respectively. A subgroup of 12 (7%) was identified where the PV diagnosis was not obvious on entry into the study but where it became clear during follow-up. 16 PV patients (9%) had verified or suspected arterial hypoxemia caused by a concomitant condition. We conclude that the increasing PV incidence rates, mainly confined to older age groups, are probably due to better case ascertainment.

Entities:  

Mesh:

Year:  1992        PMID: 1730276     DOI: 10.1111/j.1600-0609.1992.tb01788.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.

Authors:  M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson
Journal:  J Intern Med       Date:  2020-01-11       Impact factor: 8.989

Review 2.  New Therapeutic Approaches in Polycythemia Vera.

Authors:  Lorenzo Falchi; Kate J Newberry; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

Review 3.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 4.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

5.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Authors:  Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

6.  Use and risks of phosphorus-32 in the treatment of polycythaemia vera.

Authors:  Claude Parmentier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-03       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.